M. Brocco

发表

Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.

C Dacquet, M. Millan, A. Gobert, 1995, The Journal of pharmacology and experimental therapeutics.

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

M. Papp, M. Millan, A. Soumier, 2008, Psychopharmacology.

S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.

R. Schreiber, M. Millan, A. Gobert, 1999, The Journal of pharmacology and experimental therapeutics.

P.1.221 Actions of the selective melanin concentrating hormone1 receptor antagonist, (+)SNAP-7941, in models of potential antidepressant and anxiolytic activity in rodents

J. Fauchère, M. Millan, D. Cussac, 2003, European Neuropsychopharmacology.

S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo

P. Svenningsson, M. Millan, A. Gobert, 2008, Journal of Pharmacology and Experimental Therapeutics.

S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively.

M. Millan, A. Gobert, J. Rivet, 1993, European journal of pharmacology.

S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.

R. Schreiber, M. Millan, J. Rivet, 1998, The Journal of pharmacology and experimental therapeutics.

Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5‐HT2A sites for PCP‐induced locomotion in the rat

M. Millan, A. Gobert, J. Rivet, 1999, The European journal of neuroscience.

Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats.

M. Millan, V. Audinot, P. Honore, 2000, European journal of pharmacology.

Effects of chronic phencyclidine administration on the schedule-controlled behavior of rats.

M. Brocco, D. McMillan, S. K. Rastogi, 1983, The Journal of pharmacology and experimental therapeutics.

S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.

R. Schreiber, R. Jaffard, S. Hjorth, 1997, The Journal of pharmacology and experimental therapeutics.

Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.

M. Millan, D. Cussac, A. Gobert, 2001, The Journal of pharmacology and experimental therapeutics.

The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines.

M. Millan, M. Brocco, 2003, European journal of pharmacology.

The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect l-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats

M. Millan, M. Morari, M. Brocco, 2010, Neuropharmacology.

Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.

M. Millan, A. Gobert, V. Audinot, 1995, Journal of medicinal chemistry.

S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: A comparison to aprepitant (MK869) and paroxetine

M. Millan, A. Gobert, J. Rivet, 2010, European Neuropsychopharmacology.

Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: A comparison to other agents

M. Millan, B. Olivier, M. Touzard, 2008, European Neuropsychopharmacology.

Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes

M. Millan, M. Brocco, S. Girardon, 2003, Psychopharmacology.

Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake A pharmacological characterization of diverse classes of antidepressant agents

M. Millan, M. Brocco, S. Girardon, 2002, Pharmacology Biochemistry and Behavior.

S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.

M. Millan, A. Gobert, J. Rivet, 1997, The Journal of pharmacology and experimental therapeutics.

Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists

M. Millan, M. Brocco, S. Girardon, 2002, Neuropharmacology.

S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.

M. Millan, A. Gobert, J. Rivet, 2000, The Journal of pharmacology and experimental therapeutics.

S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

M. Papp, M. Millan, J. Péglion, 2001, The Journal of pharmacology and experimental therapeutics.

S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors: II. Functional Profile and a Multiparametric Comparison with Haloperidol, Clozapine, and 11 Othe

M. Millan, J. Rivet, A. Newman-Tancredi, 2000 .

Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs

M. Millan, A. Gobert, D. Watson, 2020, Neuropharmacology.

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

M. Millan, A. Gobert, M. Brocco, 2005, Psychopharmacology.

EVALUATION OF NARCOTIC AND NARCOTIC ANTAGONIST INTERACTIONS IN PRIMATES *

C. A. Robinson, M. Brocco, K. F. Killam, 1976, Annals of the New York Academy of Sciences.

The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines

M. Millan, M. Brocco, 2003 .

Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants

P. Svenningsson, M. Millan, L. Cistarelli, 2021, International journal of molecular sciences.

(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.

R. Schreiber, M. Millan, A. Gobert, 1995, The Journal of pharmacology and experimental therapeutics.

S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.

R. Schreiber, M. Millan, A. Gobert, 1998, The Journal of pharmacology and experimental therapeutics.

Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.

M. Millan, M. Brocco, Mark J Millan, 2008, Therapie.

Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents.

M. Millan, A. Gobert, J. Rivet, 2000, The Journal of pharmacology and experimental therapeutics.

Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra

M. Millan, D. Cussac, J. Rivet, 2001, Brain Research.

Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test

R. Schreiber, M. Millan, M. Brocco, 1995, Pharmacology Biochemistry and Behavior.

S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects

M. Millan, A. Gobert, J. Rivet, 2008, Journal of Pharmacology and Experimental Therapeutics.

acetamide ) , a Preferential Dopamine D 3 versus D 2 Receptor Antagonist and Potential Antipsychotic Agent : III . Actions in Models of Therapeutic Activity and Induction of Side Effects

M. Millan, A. Gobert, J. Rivet, 2007 .

The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats.

M. Millan, A. Gobert, J. Rivet, 2008, The international journal of neuropsychopharmacology.

Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA)

P. Svenningsson, M. Millan, A. Gobert, 2011, The Journal of Neuroscience.

Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.

M. Millan, A. Gobert, J. Rivet, 1994, The Journal of pharmacology and experimental therapeutics.

The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT1A receptor antagonists.

R. Schreiber, M. Millan, A. Gobert, 1994, European journal of pharmacology.

A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.

M. Millan, A. Gobert, J. Rivet, 1998, The Journal of pharmacology and experimental therapeutics.

Modification of drug effects by l-α-acetylmethadol

M. Brocco, D. McMillan, 1984, Pharmacology Biochemistry and Behavior.

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

M. Papp, M. Millan, A. Gobert, 2012, Journal of Pharmacology and Experimental Therapeutics.

Effects of chronic Δ9-tetrahyrocannabinol administration on schedule-controlled behavior of pigeons: Cross-tolerance to pentobarbital and barbital

M. Brocco, D. McMillan, L. D. Chait, 2004, Psychopharmacology.

Tolerance to d-amphetamine and lack of cross-tolerance to other drugs in rats under a multiple schedule of food presentation.

M. Brocco, D. McMillan, 1983, Journal of Pharmacology and Experimental Therapeutics.

Anxiolytic Properties of the Selective, Non-peptidergic CRF1 Antagonists, CP154,526 and DMP695: A Comparison to Other Classes of Anxiolytic Agent

M. Millan, A. Gobert, M. Brocco, 2001, Neuropsychopharmacology.

Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological, and Behavioral Characterization

M. Millan, A. Gobert, F. Lejeune, 2009, Neuropsychopharmacology.

Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone.

R. Schreiber, M. Millan, M. Brocco, 1994, European journal of pharmacology.

A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin.

R. Schreiber, M. Millan, M. Brocco, 1995, The Journal of pharmacology and experimental therapeutics.

Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors

M. Papp, M. Millan, Anne Dekeyne, 2006, Behavioural pharmacology.

Reinstatement of responding maintained by cocaine or thiamylal.

M. Brocco, W. Slikker, K. Killam, 1984, The Journal of pharmacology and experimental therapeutics.

The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats

M. Millan, D. Cussac, A. Gobert, 2004, Psychopharmacology.

Effects of trialkyltins on the schedule-controlled behavior of the pigeon.

G. Wenger, L. Chang, M. Brocco, 1987, Neurotoxicology and teratology.

S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole

M. Millan, J. Brotchie, A. Gobert, 2004, Journal of Pharmacology and Experimental Therapeutics.

WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex.

M. Millan, A. Gobert, L. Cistarelli, 1998, European journal of pharmacology.

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.

M. Millan, D. Cussac, A. Gobert, 2000, The Journal of pharmacology and experimental therapeutics.

The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats

M. Millan, A. Gobert, M. Brocco, 2000, Psychopharmacology.

S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.

M. Millan, J. Rivet, G. Lavielle, 2000, The Journal of pharmacology and experimental therapeutics.

S33138 N -[4-[2-[(3 aS ,9 bR )-8-Cyano-1,3 a ,4,9 -tetrahydro[1]-benzopyrano[3,4- a Preferential Dopamine D 3 versus D 2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo

P. Svenningsson, M. Millan, A. Gobert, 2008 .

Antipsychotic profile of the novel benzopyranopyrrole and preferential dopamine D3 receptor antagonist, S33138

M. Millan, D. Cussac, J. Brotchie, 2002, European Neuropsychopharmacology.

Comparative studies on the anti‐punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon, Geller‐Seifter and Vogel conflict procedures

W. Koek, F. Colpaert, M. Brocco, 1990, Behavioural pharmacology.

S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole

M. Papp, M. Millan, T. Sharp, 2004, Journal of Pharmacology and Experimental Therapeutics.

The novel antidepressant, S35966, is a mixed serotonin and noradrenaline reuptake inhibitor and an antagonist at α2-adrenoceptors

D. Cussac, A. Gobert, J. Rivet, 2002, European Neuropsychopharmacology.

ALLOSTERIC MODULATION OF MUSCARINIC M4 RECEPTORS IN THE TREATMENT OF SCHIZOPHRENIA: A PHARMACOLOGICAL COMPARISON OF LY2033298 VS VU0152099

M. Millan, M. Brocco, D. Dupuis, 2010, Schizophrenia Research.